Olivia Naismith

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 536 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

David P. Dearnaley, Isabel Syndikus, G. Sumo et al. · The Lancet Oncology · 2011 · 308 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 303 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Nicholas van As, Clare Griffin, Alison Tree et al. · New England Journal of Medicine · 2024 · 218 citations · Full text

Medicine, Radiation Oncology, Urology +16